Akums Drugs and Pharmaceuticals544222Routine director change
Senior VP – R&D Sunil Jaiswal resigns; relieved as Senior Management Personnel on October 31, 2026
Akums Drugs & Pharmaceuticals has informed the exchanges that Mr. Sunil Jaiswal, Senior Vice President – Research & Development and a designated Senior Management Personnel, has resigned.
By ScoutQuest · · 1 min read
- Senior Management Personnel
- Sunil Jaiswal, Senior Vice President – Research & Development
- Resignation reason
- family commitments; attained age of 61 years
- Relieving date
- October 31, 2026
Who is stepping down
- Mr. Sunil Jaiswal held the position of Senior Vice President – Research & Development at Akums Drugs and Pharmaceuticals Ltd and was also designated as a Senior Management Personnel of the company.
- The company has informed the exchanges of the cessation of his position.
Why he resigned
- The stated reason is family commitments, along with the fact that he has attained the age of 61 years.
- His resignation letter, included with the disclosure, thanks the management for the support, guidance and opportunities during his time with the company.
Timeline of the exit
- He submitted his resignation on 5th August 2026, with a request to be relieved with effect from October 30, 2026.
- After discussion, October 31, 2026 was agreed as his relieving date.
- The company's disclosure records October 31, 2026 as the date of cessation.
Handover
- In his letter he states that during his final weeks he would do everything he can to help ensure a smooth transition of his duties, and asks how he can best assist with handing over his current responsibilities.
What this means for a retail investor
- A senior management exit is a routine personnel disclosure. The role being vacated heads Research & Development, a function that matters for a pharmaceutical company's product development work.
- The reason given is personal in nature, and the note records a planned, discussed relieving date rather than an abrupt departure.
- Judge the news as a change in management personnel; the disclosure itself sets out the position, the reason, the dates and the handover intent.
Also from Akums Drugs and Pharmaceuticals
Akums Q2 FY27: revenue up 31.9% to Rs 1,342 cr, PAT up 168.3% to Rs 115 cr
2 Nov 2026
Akums Q2 FY27 revenue up 31.9% to ₹1,342 crore; buys Oriflame India's manufacturing business for ₹56 crore
2 Nov 2026
Board approves unaudited results, designates President – Operations as Senior Management Personnel
2 Nov 2026
More numbers
- Age attained by outgoing Senior VP – R&D61 years
Source: BSE · 31 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.